



iPill Platform



Active controlled pill dispensing

John Hsu MD, Co-founder
John@iPilldispenser.com



The Problem: Uncontrolled Access to Controlled Substances

Diversion




No dispensing control
No pill security



Abuse



3.3 billion unused pills enter
our cities every year



Possible Overdose



28,000 opioid prescription
deaths per year

In the COVID19 pandemic opioid overdose deaths
have increased 18% March, 29% April, 42% May 2020



The Need: Opioid Security at Home



Hospitals
Pharmacies

Opioids are
triple locked

Pyxis / OmniCell

HOME



Opioids
are free

28,000 deaths / year

The Solution: iPill_{tm} Platform

iPill APP

Actively controlled
dispensing

- ◆ Personalized ID
- ◆ Prescription adherence

iPill Dispenser

Secure storage
Safe disposal

- ◆ Patented pill destruction mechanism destroys drugs if tampered and at prescription expiration



BLE connection





Operating the iPill

Registration

Step #1 Patient gets prefilled iPill from pharmacy



Step #2 Scans QR code iPill App Automatically download



Step #3 Registers app name
birthdate
face / fingerprint
personal code



Dispensing

Step #1 Authenticate ID
Face / fingerprint & personal code



Step #2 Dispense opioid



OUD Treatment



\$166 and \$570 month¹

Plus

Inpatient **treatment cost** between
\$14,000 and \$27,000 month²

Outpatient **treatment cost** between
\$5,000 and \$10,000 for 3 months

vs.

OUD Prevention



\$50 month

Prevents

Annually

\$19,333

\$1.8 million

\$696 billion

Costs of addiction per patient

Cost per death

Cost to the US economy



Regulatory

- ✦ FDA 2018 Innovation Challenge for the Prevention and Treatment of Opioid Use Disorder
- ✦ FDA 2019 Designated Breakthrough Product (Class II Product)
- ✦ FDA 2020 Class I Registration
- ✦ CMS announces reimbursement of FDA designated Breakthrough products.

Intellectual property

- ✦ 3 Granted **Patents** 10426707, 10588824, 10709643
- ✦ PCT patents EU, UK, Canada

Pilots

- ✦ Rutgers Dental School
- ✦ UConn/ Hartford Healthcare

Awards

- ✦ UCLA 2018 Opioid Hack-A-Thon winner
- ✦ Hartford 2019 InsurTech Hub Competition winner
- ✦ American College of Cardiology 2020 Digital Health Innovation Challenge

Purchase orders 2020

- ✦ Wheeler Behavioral Treatment Centers, Connecticut
- ✦ Aspire-365 Addiction Treatment Centers



iPill Team

Management



CEO

- ♦ John Hsu MD,
- ♦ Series 7, Software integration, drug development
- ♦ Anesthesia & Pain for 28 years



CTO

- ♦ James Yang, BS,
- ♦ Software Engineer,
- ♦ Ticketmaster and Hilton Hotel apps



CSO

- ♦ Bruce Sargeant, BSEE
- ♦ Hardware Engineer
- ♦ Developer of Velodyne



Board

- ♦ Sherie Hsieh, BS Co-Founder
- ♦ Clinical Toxicologist



- ♦ Nick Spring
- ♦ Exited from medical device and biopharma company



- ♦ Peter Weinstein, PhD, JD
- ♦ IP Attorney, Baxter

Advisors



Daniel I. Sessler, MD,
Professor Editor of Anesthesiology



Jared Adams, MD, PhD
SelfCare Catalysts



Lacarya Scott, MBA
Business Strategy Development



Brian Harvey MD, PhD,
Former CDRH Dir. of FDA



Robert Nickell, PharmD
FDA pharmacy Regulations



Romy Seth, BAsC, BSc
Business Strategy Development



Matthew Clark, BA
HIPAA, Cybersecurity



Christopher Buckley, MBA
Former Pyxis/Livi Executive



Christopher Baker, MBA
Former SVP McKesson
SupplyChain/Operations



Tony Chang, BS, E.E.
Project Manager Foxconn



Sean Evins, MA
Commercialization,
Government outreach Facebook

iPill's Total Market Opportunity

There's a **\$9.2 billion*** annual revenue opportunity to prevent addiction using a tech-enabled dispensing system

Prevention

\$3 billion*
< 26 year olds

- Highest rate of prescription opioids used and abused

Treatment

\$3.5 billion*
26-54 year olds

- Highest overdose death rate
- highest rates of inpatient stays

Chronic Pain

\$2.7 billion*
55+ year olds

- (OUD) in Adults Age 55 have almost doubled since 2007



Competitive Analysis



iPill
\$50



Child
Resistant
Cap



Hero
\$399



Protex
RX
\$189



Med
Time
\$289



Auto
Pill
\$69.95



Med
Ready
\$179



Med
Smart
\$589.99



TAD
Est. \$200



Medica
Safe
Est.\$250

- Prescription adherence ↑
- Deterrence ↑
- Secure storage
- Safe disposal
- Destroys drug
- Unused opioids ↓
- Healthcare cost ↓
- Provider liability ↓
- Manufacturer liability ↓

✓✓		✓	✓	✓	✓	✓	✓	✓	✓
✓✓			✓	✓		✓	✓		
✓✓			✓✓				✓		
✓✓									
✓✓	iPill advantage iPill is the only FDA Breakthrough dispenser (Class II product) CMS declares reimbursement for FDA Breakthrough products Aug. 31, 2020								
✓✓									
✓✓									
✓✓									
✓✓									
✓✓									



iPill Market Channels

Dental Practices targeting <26 yos

- Short-sales cycle
- 10 million wisdom tooth extractions yearly in US
- prevent addiction in adolescents/ young adults from becoming addicted to post-op opioids
- \$250 million sales opportunity

Addiction/Rehab Centers targeting 26-55 yo

- Short-sales cycle
- 3.7 million patients in treatment across 1,450 centers in US
- reduce relapse risk in transitioning clients from a inpatient to outpatient service
- \$2.2B sales opportunity

Pharmacy-Insurer- Providers targeting all


- Long-sales cycle
- 100+ million prescriptions yearly for opioids
- reduction in healthcare costs by reducing risk of addiction
- \$6.75B sales opportunity



Current Raise: \$2 million Seed Equity

\$500K Invested by founders 100% founder owned

Use of Proceeds





The Platform Future **Monitors the Patient and the Pills**


FDA Class II Product

Respiratory Biosensor

Worn on the chest
to detect respiration



iPill App



Calls 911

- ✦ If respiratory distress is detected
- ✦ Stops opioid dispensing



Roadmap: Seed to Series A to Exit

\$2MM Seed

\$7-10MM Series A

EXIT



2Q20

3Q20

4Q20

1Q21-3Q21

4Q21-3Q23

4Q24

- Complete FDA Class I Registration

- Market Launch Class I product
- Work with Foxconn to shrink the iPill

- Complete Pilot with Rutgers Dental School

- Limited launch to Dental market
- Limited launch to Addiction treatment centers
- Start Pilot with Payor
- Obtain unique CPT/HCPCS code via CMS/HHS
- Start Class II study Pilot with UConn/Hartford Healthcare

- Close Series A for further commercialization
- Full launch to Dental market
- Full launch to Addiction treatment centers
- Commercialize with a PBM

- Explore structured sale

Potential Acquirors:

- Pharmacy-insurers: Aetna/CVS, Anthem/IngenioRX, Cigna, BlueCross, UnitedHealthcare-Optum, Cigna, Oscar
- Pharma (focused on opioids): Teva, Mallinckrodt, Pfizer, Actavis, Endo, Purdue
- Medical device companies: i.e. J&J, Pyxis, OmniCell
- Pharma Supply Chain: McKesson, Cardinal, AmerisourceBergen
- Digital health/tele-health companies: Amazon, Teladoc
- Digital cognitive behavioral therapy companies: PearTherapeutics, Ableto
- Addiction Rehab Centers: AloRecovery, AshleyAddictionTreatment
- Online pharmacies: Capsule, Alto, TruePill, PillPack



iPill Platform

Revolutionary
Prescription
Safety

Sherie Hsieh, cofounder
Sherie@iPilldispenser.com

[John Hsu MD, cofounder](mailto:John@iPilldispenser.com)
John@iPilldispenser.com
626-695-5985